Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Neuro Oncol 2005 7(1):77-83; DOI:10.1215/S1152851704000584
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rades, D.
Right arrow Articles by Alberti, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Duke University Press

Retrospective Clinical Studies

Well-differentiated neurocytoma: What is the best available treatment?

Dirk Rades1, Fabian Fehlauer, Katrin Lamszus, Steven E. Schild, Christian Hagel, Manfred Westphal and Winfried Alberti

Departments of Radiation Oncology (D.R., F.F., W.A.), Neurosurgery (K.L., M.W.), and Neuropathology (C.H.), University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ 85259 (S.E.S.), USA

1 Address correspondence to Dirk Rades, Department of Radiation Oncology, University Hospital Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany (Rades.Dirk{at}gmx.net).

Abstract

Most neurocytomas are well differentiated, being associated with better long-term survival than the more aggressive atypical lesions. Atypical neurocytomas are characterized by an MIB-1 labeling index >3% or atyp-ical histologic features. This analysis focuses on well-differentiated neurocytomas in order to define the optimal treatment. A case with a follow-up of 132 months is presented. The patient developed two recurrences two and four years after first surgery, each showing an increasing proliferation activity. Furthermore, all published well-differentiated neurocytoma cases were reviewed for surgery, radiotherapy, and prognosis. Additional rel-evant data were obtained from the authors. Complete resection (CTR), complete resection plus radiotherapy (CTR + RT), incomplete resection (ITR), and incomplete resection plus radiotherapy (ITR + RT) were compared for outcome by using the Kaplan-Meier method and the log-rank test. Data were complete in 301 patients (CTR, 108; CTR + RT, 27; ITR, 81; ITR + RT, 85). Local control and survival were better after CTR than after ITR (P < 0.0001 and P = 0.0085, respectively). Radiotherapy improved local control after ITR (P < 0.0001) and after CTR (P = 0.0474), but not survival (P = 0.17 and P = 1.0, respectively). In the ITR + RT group, doses ≤54 Gy (n = 33) and >54 Gy (n = 32) were not significantly different for local control (P = 0.88) and survival (P = 0.95). The data demonstrated CTR to be superior to ITR for local control and survival. After CTR and ITR, radiotherapy improved local control, but not survival. A radiation dose of 54 Gy appeared sufficient. Application of postoperative radiotherapy should be decided individually, taking into account the risk of local failure, the need for another craniotomy, and potential radiation toxicity.







  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Copyright 2005 by Society for Neuro-Oncology